HMGB1 and neoplasm: The above results suggest that the Vpr peptide can induce ICD in the LLC tumor xenograft model, leading to the exposure of CRT on the tumor cell membranes and the release of HMGB1, thereby activating pattern recognition receptors and eliciting a potent anti-tumor immune response.